Open label VLS-101 at 0.5,1.0, 1.5, 2.25, 2.5, 2.75, or 3.0 mg/kg given IV on Day 1 of repeated 21-day cycles.

Open label VLS-101 at 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, or 2.25 mg/kg given IV on Days 1 and 8 of repeated 21-day cycles.

Open label VLS-101 at 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, or 2.25 mg/kg given IV on Days 1, 8, and 15 of repeated 28-day cycles.

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Follicular Lymphoma

Marginal Zone Lymphoma

Diffuse Large B-cell Lymphoma

Richter Transformation Lymphoma

Burkitt Lymphoma

Lymphoplasmacytoid Lymphoma

T-cell Non-Hodgkin Lymphoma

Acute Lymphoid Leukemia

Acute Myeloid Leukemia

Waldenstrom Macroglobulinemia

VLS-101 Schedule 1

VLS-101 Schedule 2

VLS-101 Schedule 3

City of Hope National Medical Center

UC San Diego Moores Cancer Center

UCLA Department of Medicine - Hematology/Oncology

university of Nebraska Medical Center

Northwell Health/CLL Research and Treatment Program

Weill Cornell Medical College - New York - Presbyterian Hospital

University of Rochester Medical Center

Oregon Health & Science University

The University of Texas MD Anderson Cancer Center

Swedish Cancer Institute

A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies

A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS -101 in Subjects With Hematological Malignancies

VelosBio Inc.

Cohorts of 3 to 6 subjects will be sequentially enrolled at progressively higher dose levels within each dose schedule of VLS-101 using a 3+3 dose-escalation design.

Therapy initiation 30 days max from screening.
Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT

Diffuse Large B Cell Lymphoma

Primary Mediastinal (Thymic) Large B-cell Lymphoma

Transformed Indolent Lymphoma

Recurrent Disease

Refractory Cancer

Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6

Dr. Meirav Kedmi

Sheba medical organization

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) for Patients With Relapsed/Refractory Aggressive B Cell Lymphomas

ORR is defined as the proportion of patients having at least partial repose (PR) in interim imaging or end of chemo-immunotherapy.

Meirav Kedmi MD

Johnson & Johnson

burkitt lymphoma

tyrosine

burkitt lymphoma/tyrosine

A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

La base de dades d’herbes medicinals més completa avalada per la ciència